Immunity: The Journal of the Cancer Research Institute
is a growing sense that cancer immunology is entering a mature phase
in its development and that the long cherished hopes for the field—effective
immunotherapies for cancer—will become a reality in the coming decades.
Immunity, initially launched by the Academy of Cancer Immunology in 2001, and adopted as the official journal of the Cancer Research Institute in 2012, provides
a unifying and interactive site for the exchange and discussion
of facts, findings, and ideas about everything relevant to the aspirations
of tumor immunologists. In short, the publication is a responsive
and safe harbor for all aspects of cancer immunology.
to those who view the field as nothing more than wishful thinking
or the propensity of some recent converts to believe the field started
with their own work, those of us guiding Cancer Immunity
view cancer immunology as having deep and strong roots, and recognize
the broad base of discoveries made over the past century that provides
the field with a firm foundation.
its origins, the field has been plagued by difficulties. One arises
from the fact that cancer immunology is a hybrid discipline, and
even though the parents have shown intermittent interest in the
offspring, they have not taken responsibility for its nourishment
and growth. As a consequence, there is a random quality to the publication
record of the treasures of cancer immunology. However, nothing has
been more harmful to the field than the recurrent episodes of uncritical
enthusiasm and exaggerated claims that have punctuated the history
of cancer immunology and have done damage to its reputation. Unfortunately,
journals, funding bodies, and companies have frequently been swayed
by such unrealistic promises, opting for novelty and fashion instead
of soundness and importance. With its Editorial
Board made up of leading contributors to the founding and development
of cancer immunology, Cancer Immunity is in a unique position
to establish a tradition of excellence, consistency, and comprehensiveness.
Immunity is committed to reflecting the broad and growing influence
of cancer immunology on the study of cancer and on the search for
ways to control the disease. Both laboratory and clinical studies
are welcome, and papers and reviews will cover the full gamut of
topics of interest to tumor immunologists, from identifying cancer
antigens and characterizing the immune response to them, to developing
strategies for effective vaccine-based and antibody-based therapies.
In addition, Cancer Immunity will provide a continuing update
- The SEREX DATABASE, a repository of human tumor antigens defined
by serological expression cloning
- The rapidly growing list of human tumor peptides/proteins recognized
by CD8+ and CD4+ T cells
- The CT (cancer-testis) family of genes and antigens
- The new antigenic targets and antibody constructs being developed
for antibody-based therapies
journal provides running commentaries on topics of general interest
to cancer immunologists, such as heat shock proteins, cancer immunosurveillance,
adjuvants, immune modulators, and immunological escape mechanisms.
Finally, the origins and history of the field are explored in a
series of invited reflections by leading cancer immunologists.
join us by contributing your work and thoughts to Cancer Immunity.
A grand adventure awaits us as the full impact and importance of
cancer immunology on the study and control of cancer become evident.
to the Cancer Immunity website